
Otto O Ettala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7665459/publications.pdf Version: 2024-02-01



ΟΤΤΟ Ο ΕΤΤΛΙΛ

#	Article	IF	CITATIONS
1	Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings. Journal of Magnetic Resonance Imaging, 2018, 48, 1626-1636.	3.4	107
2	Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging, 2017, 46, 1089-1095.	3.4	75
3	Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncology, The, 2019, 20, 1602-1614.	10.7	65
4	A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). European Urology Oncology, 2021, 4, 635-644.	5.4	58
5	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). European Urology Oncology, 2021, 4, 971-979.	5.4	56
6	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine, 2019, 16, e1002813.	8.4	43
7	Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naÃ⁻ve prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 665-673.	6.4	42
8	ANO7 is associated with aggressive prostate cancer. International Journal of Cancer, 2018, 143, 2479-2487.	5.1	31
9	Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2951-2959.	6.4	26
10	Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. European Urology Oncology, 2018, 1, 525-530.	5.4	23
11	Repeatability of radiomics and machine learning for DWI: Shortâ€ŧerm repeatability study of 112 patients with prostate cancer. Magnetic Resonance in Medicine, 2020, 83, 2293-2309.	3.0	23
12	11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). Cancer Imaging, 2018, 18, 25.	2.8	22
13	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRIâ€Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTIâ€IMPROD Trials). Journal of Magnetic Resonance Imaging, 2020, 51, 1556-1567.	3.4	22
14	Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. European Urology Oncology, 2020, 3, 648-656.	5.4	18
15	Synergistic Interaction of <i>HOXB13</i> and <i>CIP2A</i> Predisposes to Aggressive Prostate Cancer. Clinical Cancer Research, 2018, 24, 6265-6276.	7.0	17
16	Factors modifying the effect of blood pressure on erectile function. Journal of Hypertension, 2015, 33, 975-980.	0.5	16
17	Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Endocrine-Related Cancer, 2018, 25, 807-819.	3.1	16
18	IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with wholeâ€mount prostatectomy sections and implications for focal therapy. Journal of Magnetic Resonance Imaging, 2019, 50, 1641-1650.	3.4	16

ΟΤΤΟ Ο ΕΤΤΑΙΑ

#	Article	IF	CITATIONS
19	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. European Urology Focus, 2019, 5, 443-448.	3.1	16
20	High-Intensity Physical Activity, Stable Relationship, and High Education Level Associate with Decreasing Risk of Erectile Dysfunction in 1,000 Apparently Healthy Cardiovascular Risk Subjects. Journal of Sexual Medicine, 2014, 11, 2277-2284.	0.6	15
21	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. World Journal of Urology, 2020, 39, 1879-1887.	2.2	15
22	Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps. European Radiology, 2021, 31, 379-391.	4.5	15
23	Antibiotic susceptibility of intestinal <i>Escherichia coli</i> in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU International, 2018, 122, 203-210.	2.5	14
24	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. Npj Precision Oncology, 2021, 5, 35.	5.4	13
25	A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Scientific Reports, 2021, 11, 8650.	3.3	10
26	Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3723-3731.	6.4	10
27	Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. European Urology Focus, 2021, 7, 522-531.	3.1	10
28	Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Bladder Cancer, 2019, 5, 273-279.	0.4	9
29	Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. World Journal of Urology, 2020, 38, 1001-1007.	2.2	9
30	Detection of Prostate Cancer Using Biparametric Prostate <scp>MRI</scp> , Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. Journal of Magnetic Resonance Imaging, 2022, 55, 465-477.	3.4	9
31	Stratification of aggressive prostate cancer from indolent disease—Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 255.e15-255.e22.	1.6	8
32	<i>ANO7</i> rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. Anticancer Research, 2019, 39, 5353-5359.	1.1	7
33	The variant rs77559646 associated with aggressive prostate cancer disrupts <i>ANO7</i> mRNA splicing and protein expression. Human Molecular Genetics, 2022, 31, 2063-2077.	2.9	7
34	Erectile dysfunction cannot be used in primary screening of pre-diabetes. Diabetes Research and Clinical Practice, 2015, 108, e60-e62.	2.8	6
35	Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial. European Urology Focus, 2022, 8, 1246-1252.	3.1	6
36	Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings. Journal of Magnetic Resonance Imaging, 2018, 48, spcone-spcone.	3.4	5

OTTO O ETTALA

#	Article	IF	CITATIONS
37	Incidence of and mortality from Bacille Calmetteâ€Guérin (BCG) infections after BCG instillation therapy. BJU International, 2022, 129, 737-743.	2.5	5
38	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open, 2022, 12, e050264.	1.9	5
39	Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmetteâ€Guérin (BCG) treatment. BJU International, 2019, 123, 246-251.	2.5	4
40	Does every Clavien-Dindo complication matter? A national multi-center study in kidney cancer surgery. Scandinavian Journal of Urology, 2021, 55, 441-447.	1.0	4
41	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machineâ€Learning Techniques. Journal of Magnetic Resonance Imaging, 2020, 51, 1540-1553.	3.4	3
42	Critical evaluation of the subcutaneous engraftments of hormone naÃ ⁻ ve primary prostate cancer. Translational Andrology and Urology, 2020, 9, 1120-1134.	1.4	3
43	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Scientific Reports, 2020, 10, 9407.	3.3	3
44	Clinical markers of morbidity, mortality and survival in bladder cancer patients treated with radical cystectomy. A systematic review. Scandinavian Journal of Urology, 2020, 54, 267-276.	1.0	3
45	Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer. Nuclear Medicine Communications, 2022, Publish Ahead of Print, .	1.1	3
46	Uptake of ¹⁸ F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 205-213.	1.0	3
47	Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study International Journal of Impotence Research, 2020, 32, 420-425.	1.8	2
48	Reply to Joshua S. Jue and Mahmoud Alameddine's Letter to the Editor re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol 2020;3:648–656. European Urology Oncology, 2020, 3, 711-712.	5.4	2
49	Response to the Letter to the Editor: Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2672-2673.	6.4	2
50	Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression. Cancers, 2022, 14, 278.	3.7	2
51	How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. Acta Radiologica Open, 2021, 10, 205846012110607.	0.6	1
52	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) Tj ETQq0 0 0	rg ₿ĩ.∮ Ove	rloak 10 Tf 50
53	Comment on: Exercise Overcomes Possible Influences of Race and Obesity. Journal of Sexual Medicine, 2015, 12, 1211.	0.6	0

⁵⁴ Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naà ve men. Scandinavian Journal of Urology, 2020, 54, 7-13. 1.0 0

#	Article	IF	CITATIONS
55	Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World Journal of Urology, 2022, , 1.	2.2	Ο
56	Intraoperative complications in kidney tumor surgery: critical grading for the European Association of Urology intraoperative adverse incident classification. Scandinavian Journal of Urology, 2022, 56, 293-300.	1.0	0